Liver
- Home
- Cancer Infomation
Etiology & Risk Factors
The pathogenesis of HCC is almost uniquely tied to chronic inflammation and subsequent cirrhosis.
1. Primary Causes & Environmental Triggers
- Viral Hepatitis: Chronic Hepatitis B (HBV) and Hepatitis C (HCV) remain the leading global drivers, though incidence is shifting due to effective antivirals and vaccination.
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Formerly NAFLD/NASH, this is now the fastest-growing etiology in Western populations, linked to obesity and Type 2 Diabetes.
- Aflatoxin B1 Exposure: A potent dietary carcinogen from Aspergillus molds found in contaminated grains, particularly prevalent in sub-Saharan Africa and Southeast Asia.
- Chronic Alcohol Consumption: Induces cirrhosis via oxidative stress and acetaldehyde-mediated DNA damage.
2. Genetic Predispositions
- Specific Mutations: TERT promoter mutations are the earliest and most frequent (~60%) somatic alterations. Other key drivers include TP53 (associated with aflatoxin and worse prognosis) and CTNNB1.
- Hereditary Syndromes: Hereditary Hemochromatosis (HFE gene mutations) significantly elevates risk due to iron overload.
- Alpha-1 Antitrypsin deficiency and Wilson’s disease are less common but notable triggers.
Clinical Manifestations (Symptoms)
Liver cancer is often “clinically silent” until the disease reaches an advanced stage or causes decompensation of underlying cirrhosis.
Early-Stage:
- Often asymptomatic; detected via surveillance ultrasound in known cirrhotic patients.
- Vague upper abdominal pain or fullness.
Advanced-Stage:
- Decompensation: New-onset ascites, variceal bleeding, or hepatic encephalopathy.
- Constitutional: Jaundice, pruritus, cachexia, and unexplained weight loss.
- Physical Findings: Hepatomegaly (often nodular) and a bruit over the liver.
Paraneoplastic Syndromes:
HCC is known for diverse metabolic paraneoplastic manifestations:
- Hypoglycemia: Due to high metabolic demand of the tumor or IGF-II secretion.
- Erythrocytosis: Resulting from ectopic erythropoietin production.
- Hypercalcemia: Linked to parathyroid hormone-related protein (PTHrP).
Diagnostic Workup
The diagnosis of HCC is unique in oncology because, in the context of cirrhosis, it can be made through non-invasive imaging criteria without a mandatory biopsy.
1. The Gold Standard: LI-RADS
The Liver Imaging Reporting and Data System (LI-RADS) standardizes the interpretation of CT and MRI. A LI-RADS 5 classification is definitive for HCC in high-risk patients.
2. Biomarkers & Liquid Biopsies
- Alpha-Fetoprotein (AFP): The most used biomarker, though limited by sensitivity. A rising trend is more significant than a single value.
- PIVKA-II (DCP): Often used in conjunction with AFP to increase diagnostic yield.
- Liquid Biopsy (ctDNA/cfDNA): liquid biopsies are utilized to monitor for Molecular Residual Disease (MRD) and to identify actionable mutations without the risks of percutaneous needle tract seeding.
Common Investigations & Staging
Diagnostic Imaging and Staging Workup for Hepatocellular Carcinoma
Imaging Modalities
- Multiphasic CT/MRI: Rationale is to identify arterial phase hyperenhancement and delayed "washout," the hallmark of HCC vascularity.
- Gadoxetic Acid (Primovist/Eovist) MRI: Preferred for detecting sub-centimeter lesions and distinguishing regenerative nodules from early HCC.
- PET-CT: Generally not standard for HCC diagnosis (due to low FDG-avidity in well-differentiated tumors) but useful for detecting extrahepatic metastasis.
Treatment Overview
Management is dictated by both the tumor stage and the functional reserve of the liver (Child-Pugh Score).
1. Surgery
- Resection: For non-cirrhotic patients or cirrhotics with preserved liver function and no portal hypertension.
- Liver Transplantation: The "ideal" treatment as it addresses both the tumor and the underlying cirrhosis. Generally adheres to the Milan Criteria.
- Approach: Robotic-assisted and laparoscopic resections have become the standard for peripheral lesions to minimize "collateral" surgical damage to the liver.
2. Radiotherapy & Loco-regional Therapy
- SBRT (Stereotactic Body Radiation Therapy): Used as a bridge to transplant or for local control in patients ineligible for surgery.
- TARE (Y-90 Radioembolization): Delivery of radioactive microspheres directly via the hepatic artery.
- Proton Therapy: Utilized for large central tumors where sparing the surrounding non-tumorous liver is critical.
3. Systemic Therapy
- First-Line Immunotherapy (Standard): Atezolizumab + Bevacizumab (IMbrave150) or Durvalumab + Tremelimumab (HIMALAYA) are the preferred regimens for advanced disease.
- Targeted Therapies (TKIs): Sorafenib and Lenvatinib remain vital options for patients with contraindications to immunotherapy.
- Second-Line: Cabozantinib, Regorafenib, or Ramucirumab.
Emerging Therapies
- GPC3-Targeted CAR-T Cells: Early-phase data shows promise for Glypican-3 targeted chimeric antigen receptor T-cell therapy in refractory HCC.
- Personalized Neoantigen Vaccines: mRNA-based vaccines tailored to the patient’s specific tumor mutations, used in the adjuvant setting to prevent recurrence.
- AI-Enhanced LI-RADS: Real-time artificial intelligence integration into radiology workflows to reduce inter-observer variability in staging.
Medical Disclaimer
This guide is intended for healthcare professionals and is based on clinical data available.
It is not a substitute for professional medical advice, diagnosis, or treatment.
Always consult the latest NCCN or local institutional protocols when making treatment decisions.